ArticleIndian journal of ophthalmology2019
Intermediate-term outcome of Aurolab aqueous drainage implant.
Article in Indian journal of ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The long-term surgical outcomes of the Aurolab aqueous drainage implant versus the Ahmed glaucoma valve for refractory pediatric glaucoma in Saudi children.Indian journal of ophthalmology · 2025Article
- Efficacy and Safety of Aurolab Aqueous Drainage Implant Compared With Baerveldt Glaucoma Implant for Refractory Glaucoma at One Year: A Systematic Review and Meta-Analysis.Journal of ophthalmology · 2024Review
- Commentary: Aurolab aqueous drainage implant: Miles to go.Indian journal of ophthalmology · 2022Article
- Safety and efficacy of Aurolab aqueous drainage implant in refractory glaucoma: A prospective study.Indian journal of ophthalmology · 2022Article
- Honeycomb epithelial oedema due to ripasudil: clinical, optical coherence tomography and histopathological correlation.BMJ case reports · 2022Article
- Retinal detachment in eyes treated with Aurolab aqueous drainage implant for refractory glaucoma - Incidence and outcomes.Indian journal of ophthalmology · 2022Article
- Commentary: Placement of the tube of a glaucoma drainage device: Different horses for different courses.Indian journal of ophthalmology · 2022Article
- Pars plana Aurolab aqueous drainage implantation for refractory glaucoma: Outcome of a new modified technique.Indian journal of ophthalmology · 2022Article
- Pars plana implantation of glaucoma drainage devices - The way to succeed in refractory glaucoma.Indian journal of ophthalmology · 2021Article
- Surgical outcomes of the Aurolab aqueous drainage implant (AADI) versus the Ahmed glaucoma valve for refractory paediatric glaucoma in Middle Eastern children.BMJ open ophthalmology · 2021Article
- Commentary: Aurolab aqueous drainage implant: Posterior versus anterior segment implantation.Indian journal of ophthalmology · 2019Article
- Commentary: Clinical outcome of a nonvalved Aurolab aqueous drainage implant in posterior segment versus anterior chamber.Indian journal of ophthalmology · 2019Article
- Commentary on: Glaucoma drainage devices: Boon or bane.Indian journal of ophthalmology · 2019Article
- Intermediate-term outcome of Aurolab aqueous drainage implant in refractory glaucoma.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological SocietyArticle
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report the intermediate-term safety and efficacy of Aurolab aqueous drainage implant (AADI) in patients with glaucoma.
methodsRetrospective review of patients who underwent AADI between January 2013 and December 2016. Patients aged >16 years and with a minimum follow-up of 6 months were included. Success was defined as complete when the intraocular pressure was ≥6 and ≤21 mmHg without antiglaucoma medication and as qualified if those requiring additional antiglaucoma medications were included.
resultsThe study included 55 patients (55 eyes) with a mean age ± standard deviation (SD) of 47.3 ± 18.1 years with a mean follow-up of 16.7 ± 11.4 months. Mean intraocular pressure reduced from 30.8 ± 11.1 mmHg to 13.1 ± 4.7, 14.1 ± 4.8, 15.7 ± 2.5 (P < 0.001) mmHg at 6 months, 1 year, and 2 years, respectively. The mean number of antiglaucoma medications reduced from 3.4 ± 1 to 0.8 ± 1.2, 0.7 ± 1.1, 0.8 ± 1 (P < 0.001) at 6 months, 1 year, and 2 years, respectively. The cumulative probability of complete and qualified success was 62% and 100% at 6 months, 54% and 92% at 1 year, and 43% and 88% at 2 years, respectively. Four patients failed during the follow-up period. Postoperative complication occurred in 28 eyes (51%), of which 17 eyes (31%) required intervention.
conclusionAADI is a safe and effective treatment for the control of intraocular pressure in patients with glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.